THE OUTPATIENT BASED REGISTRY RECVASA: PROSPECTIVE FOLLOW-UP DATA, RISK EVLUATION AND OUTCOMES IN CARDIOVASCULAR PATIENTS

Aim. To evaluate, under the frame of prospective registry, the 12-month outcomes and risks in patients with arterial hypertension (AH), ischemic heart disease (CHD), chronic heart failure (CHF) and atrial fibrillation (AF) in the real outpatient practice in Ryazan Region. Material and methods. Into the outpatient registry RECVASA (REgistry of CardioVAScular diseases) totally 3690 patients included with AH, CHD, CHF, AF and their comorbidity, visited 3 outpatient institutions in Ryzan city: 1047 (28%) of men and 2643 women, mean age 66,1±12,9 y.o. The estimation of 12-mint risk of events fter inclusion in registry RECVASA was done for 3619 (98,1%) participants. Results. By 12 month after inclusion 168 patients (4,6%) died, had stroke (S) — 62 (1,7%), myocardial infarction (MI) — 26 (0,7%), cardiovascular surgery (CVS) — 6 (0,2%). Totally 235 hospitalizations for CVD registered. The risk of death, MI development and S had been increasing by 5-9% every year of patient age, and CVD hospitalization — decreased by 2%. Combined death risk and cardiovascular death risk were significantly higher (1,3-6,4 times) with anamnesis of MI, S, diabetes mellitus (DM), chronic obstructive lung disease (COPD), CHF of 3-4 functional class (FC), in males and with blood pressure (BP) <110/75 mmHg, heart rate (HR) >90 bpm, glomerular filtration rate (GFR) <45 ml/min. Higher MI risk (1,8-3,4 times) was linked to the anamnesis of diabetes and MI, angina pectoris (FC 3-4) and GFR <45 ml/min. MI risk was higher by 2,4-7,2 times in patients with anamnesis of MI, permanent AF, and with combinations of AH, CHD, CHF and AF, with BP <110/75 mmHg and >180/110 mmHg, HR >90/min. Risk of all-cause death was lower in those who received p-adrenoblockers, angiotensin-converting enzyme inhibitors (iACE) and angiotensin receptor blockers (ARB) 1,4-1,5 times, death from cardiovascular causes — with iACE and ARB — 2 times lower. Patients on p-blockers had 1,8 times lower risk of MI. Conclusion. Prospective follow-up of cardiovascular patients under the frame of RECVASA registry showed significant negative influence on prognosis the following: age, male gender, anamnesis of MI and S, DM, COPD, CHF (3-4 FC), angina (3-4 FC), permanent AF, BP <110/75 and >180/110 mmHg, GFR <45 ml/min, HR >90/min, combination of AH, CHD, CHF and AH, CHD, CHF, AF. Positive influence on prognosis with CVD had treatment with p-adrenoblockers, iACE, ARB. 

1. WHO Global InfoBase. Available at: https://apps.who.int/infobase/Mortality.aspx. Accessed by 12.01.2015.

2. Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and Stroke Statistics -2013 Update: A Report From the American Heart Association. Circulation 2013; 127: e6-245.

3. Perk J, de Backer BG, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33: 1635-701.

4. Gliklich RE. Registries for Evaluating Patient Outcomes: A User's Guide. Rockville, MD: Agency for Healthcare Research and Quality; 2010.

5. Martsevich SYu, Ginzburg ML, Kutishenko NP, et al. The LIS study (Lyubertsy study of mortality in patients with acute myocardial infarction). Evaluation of the pharmacotherapy. Part 1. Treatment of patients before myocardial infarction and its influence on hospital mortality rate. Rational Pharmacother Card 2012; 8(5): 681-4. Russian (Martsevich S. Yu., Ginzburg M. L., Kutishenko N. P., Deev A. D. i dr. Issledovanie LIS (Lyuberetskoe issledovanie smertnosti bol'nykh, perenesshikh ostryi infarkt miokarda). Otsenka lekarstvennoi terapii. Chast' 1. Kak lechatsya bol'nye pered infarktom miokarda, i kak eto vliyaet na smertnost' v statsionare. RFK 2012;8(5):681 -4).

6. Tang EW, Wong CK, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J 2007; 153(1): 29-35.

7. Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registryin the FIELD (GARFIELD). Am Heart J 2012; 163(1): 13-9.e1.

8. Camm AJ, Breithardt G, Crijns H, et al. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). JACC 2011; 58(5): 493-501.

9. Boytsov SA, Krivonos OV, Oshchepkova EV, et al. Evaluation of the measures aimed at reducing the death rate from cardiovascular disease in the regions included in the program in 2008, according to the monitoring of the Health Ministry and the Russian Register of ACS. Menedzher Zdravookhraneniya 2010; (5): 19-29. Russian (Boitsov S. A., Krivonos O.V., Oshchepkova E. V. i dr. Otsenka effektivnosti realizatsii meropriyatii, napravlen¬nykh na snizhenie smertnosti ot sosudistykh zabolevanii v regionakh, vklyuchennykh v programmu v 2008 godu, po dannym monitoringa Minzdravsotsrazvitiya Rossii i Registra OKS. Menedzher Zdravookhraneniya 2010; (5): 19-29).

10. Gafarov VV, Gafarova AV, Blaginina MJu. The WHO program "Register of acute myocardial infarction": 25-year epidemiological study of myocardial infarction in Russia (1977-2001). Kardiologija 2005; (8):48-50). Russian (Gafarov V. V., Gafarova A. V., Blaginina M. Yu. Programma VOZ "Registr ostrogo infarkta miokarda": 25-letnee epidemiologicheskoe issledovanie infarkta miokarda v Rossii (1977-2001). Kardiologiya 2005; (8): 48-50).

11. Erlikh AD, Gratsianskiy NA. Acute coronary syndrome without ST elevation in the real practice of Russian hospitals. Comparative data registers "RECORD-2" and "RECORD". Kardiologija 2012; (10): 9-16. Russian (Erlikh A. D., Gratsianskii N. A. Ostryi koronarnyi sindrom bez pod"emov ST v real'noi praktike rossiiskikh statsionarov. Sravnitel'nye dannye registrov "REKORD-2" i "REKORD". Kardiologiya 2012; (10): 9-16).

12. Boytsov SA, Jakushin SS, Martsevich SYu, et al. Outpatient polyclinic case of cardiovascular diseases in the Ryazan region (RECVASA): key challenges, the experience of creating and first results. Ration Pharmacother Cardiol 2013; 9 (1): 4-14. Russian (Boitsov S.A., Yakushin S. S., Martsevich S. Yu. i dr. Ambulatorno-poliklinicheskii registr kardiovaskulyarnykh zabolevanii v Ryazanskoi oblasti (REKVAZA): osnovnye zadachi, opyt sozdaniya i pervye rezul'taty. RFK 2013; 9(1): 4-14).

13. Loukyanov MM, Boytsov SA, Yakushin CC, et al. Outpatient registry of cardiovascular diseases (RECVASA): prospective follow up data, estimation of risks and outcomes in patients with atrial fibrillation. Ration Pharmacother Cardiol 2014; 10 (5): 470¬80. Russian (Luk'yanov M. M., Boitsov S. A., Yakushin C. S. i dr. Ambulatorno- poliklinicheskii Registr KardioVAskulyarnykh ZAbolevanii: dannye prospektivnogo nablyudeniya, otsenka riska i iskhody u bol'nykh s fibrillyatsiei predserdii. RFK 2014; 10(5): 470-80).

14. Boytsov SA, Loukyanov MM, Yakushin CC, et al. Cardiovascular diseases registry (RECVASA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient-polyclinic practice. Cardiovascular Therapy and Prevention 2014;13(6): 44-50. Russian (Boitsov S. A., Luk'yanov M. M., Yakushin C. S. i dr. Registr kardiovaskulyarnykh zabolevanii (REKVAZA): diagnostika, sochetannaya serdechno-sosudistaya patologiya, soputstvuyushchie zabolevaniya i lechenie v usloviyakh real'noi ambulatorno-poliklinicheskoi praktiki. Kardiovaskulyarnaya terapiya i profilaktika 2014; 13(6): 44-50).